JP2009530613A - 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用 - Google Patents

多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用 Download PDF

Info

Publication number
JP2009530613A
JP2009530613A JP2009500495A JP2009500495A JP2009530613A JP 2009530613 A JP2009530613 A JP 2009530613A JP 2009500495 A JP2009500495 A JP 2009500495A JP 2009500495 A JP2009500495 A JP 2009500495A JP 2009530613 A JP2009530613 A JP 2009530613A
Authority
JP
Japan
Prior art keywords
gelsolin
subject
level
multiple sclerosis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009500495A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009530613A5 (enExample
Inventor
トーマス ピー． ストッセル，
ポ−シュン リー，
ボニー ディッテル，
カタジナ マレシュ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of JP2009530613A publication Critical patent/JP2009530613A/ja
Publication of JP2009530613A5 publication Critical patent/JP2009530613A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
JP2009500495A 2006-03-15 2007-03-14 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用 Pending JP2009530613A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78250906P 2006-03-15 2006-03-15
PCT/US2007/006581 WO2007106577A2 (en) 2006-03-15 2007-03-14 Gelsolin in the treatment and diagnosis of neurological disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011271607A Division JP6203995B2 (ja) 2006-03-15 2011-12-12 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用

Publications (2)

Publication Number Publication Date
JP2009530613A true JP2009530613A (ja) 2009-08-27
JP2009530613A5 JP2009530613A5 (enExample) 2010-05-06

Family

ID=38510104

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009500495A Pending JP2009530613A (ja) 2006-03-15 2007-03-14 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用
JP2011271607A Active JP6203995B2 (ja) 2006-03-15 2011-12-12 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011271607A Active JP6203995B2 (ja) 2006-03-15 2011-12-12 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用

Country Status (11)

Country Link
US (2) US8440622B2 (enExample)
EP (1) EP2002258B1 (enExample)
JP (2) JP2009530613A (enExample)
CN (1) CN101460843B (enExample)
CA (1) CA2680333C (enExample)
DK (1) DK2002258T3 (enExample)
ES (1) ES2651619T3 (enExample)
HU (1) HUE035980T2 (enExample)
PL (1) PL2002258T3 (enExample)
PT (1) PT2002258T (enExample)
WO (1) WO2007106577A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537516A (ja) * 2010-07-07 2013-10-03 アースローゲン ゲーエムベーハー 自己タンパク質の製造方法
JP2018523134A (ja) * 2015-05-12 2018-08-16 ビオメリューＢｉｏｍｅｒｉｅｕｘ 集中治療室入院患者が播種感染症を発症するリスクの予測
JP2020187143A (ja) * 2016-06-29 2020-11-19 学校法人自治医科大学 バイオマーカー判定方法、バイオマーカー、診断用組成物、及び診断用キット
JP2021514660A (ja) * 2018-03-05 2021-06-17 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 末梢神経障害を診断及び／又は治療するための方法及びキット

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
WO2005046454A2 (en) * 2003-11-12 2005-05-26 Trustrees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
KR101314461B1 (ko) 2004-05-12 2013-10-07 더 브리검 앤드 우먼즈 하스피털, 인크. 감염 치료를 위한 겔솔린의 용도
JP4348631B2 (ja) * 2005-03-29 2009-10-21 セイコーエプソン株式会社 半導体素子の製造方法
EP3279663B1 (en) 2006-03-15 2021-07-28 The Brigham and Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
DK2250280T3 (en) 2008-01-25 2015-03-09 Gen Hospital Corp THERAPEUTIC USES OF gelsolin in renal failure
WO2009124226A2 (en) * 2008-04-03 2009-10-08 The Trustees Of The University Of Pennsylvania Gelsolin uses in neurological disorders
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
EP2653476B1 (en) * 2010-12-16 2017-04-26 National Institute of Advanced Industrial Science And Technology Method for enrichment and separation of spinal fluid glycoprotein, method for searching for marker for central nervous system diseases which utilizes the aforementioned method, and marker for central nervous system diseases
KR101416954B1 (ko) 2012-09-12 2014-07-16 한양대학교 산학협력단 조혈세포 분화 유도 방법
WO2015137738A1 (ko) * 2014-03-11 2015-09-17 한양대학교 산학협력단 혈액질환 진단
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
BR112019017724A2 (pt) 2017-03-26 2020-03-31 Mapi Pharma Ltd. Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla
US20230181027A1 (en) * 2019-06-28 2023-06-15 Mayo Foundation For Medical Education And Research Methods and materials for treating neuromyelitis optica spectrum diseases
CN116615216A (zh) * 2020-09-23 2023-08-18 生物保护医疗公司 用于鉴定和治疗微粒相关疾病和病症的组合物和方法
CA3196026A1 (en) * 2020-09-23 2022-03-31 Bioaegis Therapeutics Inc. Compositions and methods for identifying and treating microparticle-associated diseases and conditions

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US627353A (en) * 1899-06-20 Cis robinson
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
CA2016227A1 (en) 1989-05-18 1990-11-18 Xandra O. Breakefield Genetic diagnosis of torsion dystonia
US5464817A (en) 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
DK0526544T3 (da) 1990-04-11 1999-06-21 Brigham & Womens Hospital Terapeutiske anvendelser af actinbindende forbindelser
EP0481070A1 (en) 1990-05-04 1992-04-22 Biogen, Inc. Multimeric gelsolin fusion constructs
US5571511A (en) 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
US5360350A (en) 1991-08-23 1994-11-01 The Whitaker Corporation Sealant compositions and sealed electrical connectors
US5691160A (en) 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
US5593964A (en) 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
JP3914272B2 (ja) 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5804427A (en) 1995-05-19 1998-09-08 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
US5925529A (en) 1995-06-07 1999-07-20 The Regents Of The University Of California Method for discovery of peptide agonists
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
EP0941108B1 (en) 1996-12-04 2002-10-16 Renovo Limited Wound healing and treatment of fibrosis
EP2305235A1 (en) 1997-04-02 2011-04-06 The Brigham And Women's Hospital, Inc. Means of ascertaining an individual's risk profile for atherosclerotic disease
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6409599B1 (en) 1999-07-19 2002-06-25 Ham On Rye Technologies, Inc. Interactive virtual reality performance theater entertainment system
AU2002225219A1 (en) 2001-01-26 2002-08-06 Oxford Glycosciences (Uk) Ltd Diagnosis and treatment of multiple sclerosis
EP1249244A1 (en) 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
WO2004035008A2 (en) 2002-02-06 2004-04-29 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
AU2003226401A1 (en) 2002-04-16 2003-11-03 The Brigham And Women's Hospital, Inc. Gelsolin as a prognostic marker of artherosclerotic diseases
AU2003253014A1 (en) 2002-06-21 2004-01-06 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
WO2004082617A2 (en) 2003-03-14 2004-09-30 Ppd Biomarker Discovery Sciences, Llc Biological markers for diagnosing rheumatoid arthritis
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
WO2005046454A2 (en) 2003-11-12 2005-05-26 Trustrees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
KR101314461B1 (ko) 2004-05-12 2013-10-07 더 브리검 앤드 우먼즈 하스피털, 인크. 감염 치료를 위한 겔솔린의 용도
EP1753455A2 (en) * 2004-06-04 2007-02-21 Genentech, Inc. Method for treating multiple sclerosis
DK1929297T3 (da) * 2005-09-29 2013-03-04 Caprion Proteomics Usa Llc Biomarkører for dissemineret sklerose og fremgangsmåder til anvendelse heraf
EP3279663B1 (en) 2006-03-15 2021-07-28 The Brigham and Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
DK2250280T3 (en) 2008-01-25 2015-03-09 Gen Hospital Corp THERAPEUTIC USES OF gelsolin in renal failure

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537516A (ja) * 2010-07-07 2013-10-03 アースローゲン ゲーエムベーハー 自己タンパク質の製造方法
JP2018523134A (ja) * 2015-05-12 2018-08-16 ビオメリューＢｉｏｍｅｒｉｅｕｘ 集中治療室入院患者が播種感染症を発症するリスクの予測
JP2020187143A (ja) * 2016-06-29 2020-11-19 学校法人自治医科大学 バイオマーカー判定方法、バイオマーカー、診断用組成物、及び診断用キット
JP2021514660A (ja) * 2018-03-05 2021-06-17 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 末梢神経障害を診断及び／又は治療するための方法及びキット
JP7101252B2 (ja) 2018-03-05 2022-07-14 アカデミア シニカ 末梢神経障害を診断及び／又は治療するための方法及びキット

Also Published As

Publication number Publication date
PL2002258T3 (pl) 2018-06-29
HUE035980T2 (hu) 2018-06-28
JP2012053071A (ja) 2012-03-15
EP2002258A2 (en) 2008-12-17
US20130230455A1 (en) 2013-09-05
WO2007106577A2 (en) 2007-09-20
CN101460843B (zh) 2018-06-22
PT2002258T (pt) 2017-12-18
EP2002258A4 (en) 2009-03-18
US8440622B2 (en) 2013-05-14
CA2680333A1 (en) 2007-09-20
CN101460843A (zh) 2009-06-17
EP2002258B1 (en) 2017-09-27
ES2651619T3 (es) 2018-01-29
JP6203995B2 (ja) 2017-09-27
DK2002258T3 (en) 2018-01-02
WO2007106577A3 (en) 2008-10-16
US20100021428A1 (en) 2010-01-28
CA2680333C (en) 2016-10-25

Similar Documents

Publication Publication Date Title
JP6203995B2 (ja) 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用
JP6568144B2 (ja) 炎症性疾患の診断および処置のためのゲルゾリンの使用
US9617596B2 (en) Biomarkers predictive for clinical response for glatiramer acetate
WO2016033187A1 (en) Use of gelsolin in the treatment and diagnosis of sickle cell disease
HK1124664B (en) Use of gelsolin to treat multiple sclerosis and to diagnose neurologic diseases
HK1124664A (en) Use of gelsolin to treat multiple sclerosis and to diagnose neurologic diseases
AU2013202205B2 (en) Use of Gelsolin to Diagnose and Treat Inflammatory Disease
HK1250781B (en) Use of gelsolin to diagnose and treat inflammatory diseases
HK1127121B (en) Use of gelsolin to diagnose and treat inflammatory diseases
HK1127121A (en) Use of gelsolin to diagnose and treat inflammatory diseases
WO2009124226A2 (en) Gelsolin uses in neurological disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110610

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110909

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110913

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110916

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120725